{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T16:30:30Z","timestamp":1772641830524,"version":"3.50.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Genetics and Cytogenetics"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.cancergencyto.2005.10.005","type":"journal-article","created":{"date-parts":[[2006,5,7]],"date-time":"2006-05-07T11:12:53Z","timestamp":1147000373000},"page":"74-77","source":"Crossref","is-referenced-by-count":7,"title":["Emergence of chronic myelogenous leukemia in a patient with primary thrombocythemia and absence of BCR\/ABL rearrangement"],"prefix":"10.1016","volume":"167","author":[{"given":"Jesus M.","family":"Cesar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Cabello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cancergencyto.2005.10.005_bib1","first-page":"258","article-title":"Clonal analysis of chronic myeloproliferative disorders using X-linked DNA polymorphisms","volume":"4","author":"Anger","year":"1990","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib2","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib4","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/ajh.2830270202","article-title":"Clinical presentation and natural history of patients with essential Thrombocythemia and the Philadelphia chromosome","volume":"27","author":"Stoll","year":"1988","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib5","first-page":"1241","article-title":"Chronic myeloid leukemia of thrombocytemic onset: a CML subtype with distinct hematological and molecular features","volume":"10","author":"Cervantes","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib6","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1365-2141.1988.tb02427.x","article-title":"Essential Thrombocythemia and the Philadelphia chromosome","volume":"70","author":"Morris","year":"1988","journal-title":"Br J Haematol"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib7","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1182\/blood.V90.7.2768","article-title":"BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential Thrombocythemia patients: clinical presentation","volume":"90","author":"Blickstein","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib8","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1034\/j.1600-0609.2003.00043.x","article-title":"Emergence of Philadelphia positive chronic myeloid leukaemia during treatment with hydroxyurea for Philadelphia negative essential thrombocythaemia","volume":"70","author":"Wahlin","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib9","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1309\/K58EWK4HPD51U3BE","article-title":"Platelet dysfunction in primary thrombocythemia using the platelet function analyzer (PFA-100)","volume":"123","author":"Cesar","year":"2005","journal-title":"Am J Clinic Pathol"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowlwy","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib11","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"De Klein","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib12","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0165-1110(87)90029-7","article-title":"Oncogene activation by chromosomal rearrangement in chronic myelocytic leukaemia","volume":"186","author":"De Klein","year":"1987","journal-title":"Mutation Research"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0165-4608(97)00263-X","article-title":"Chronic myeloid leukaemia with thrombocythemic onset may be associated with different BCR\/ABL variant transcripts","volume":"101","author":"Emilia","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib14","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/ajh.20257","article-title":"Every case of essential thrombocythemia should be tested for the Philadelphia chromosome","volume":"78","author":"Rice","year":"2005","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cancergencyto.2005.10.005_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate: a new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N Engl J Med"}],"container-title":["Cancer Genetics and Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460805005984?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165460805005984?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,14]],"date-time":"2020-04-14T14:37:13Z","timestamp":1586875033000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165460805005984"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0165460805005984"],"URL":"https:\/\/doi.org\/10.1016\/j.cancergencyto.2005.10.005","relation":{},"ISSN":["0165-4608"],"issn-type":[{"value":"0165-4608","type":"print"}],"subject":[],"published":{"date-parts":[[2006,5]]}}}